Clinical Efficacy and Safety of Ivacaftor/Lumacaftor Combination in Patients with Cystic Fibrosis: International Studies Review
Cystic fibrosis is an autosomal recessive disease caused by structure abnormalities in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. It is characterized by severe course and poor prognosis without or with insufficient treatment. Approval of pathogenetic therapy medications, CF...
Saved in:
| Main Authors: | Nataliya Yu. Kashirskaya, Nika V. Petrova, Rena A. Zinchenko |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2021-12-01
|
| Series: | Вопросы современной педиатрии |
| Subjects: | |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/2794 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluation of the Effectiveness of Using the CFTR Modulator Ivacaftor/Lumacaftor in Children with Cystic Fibrosis in the Sverdlovsk Region (Prospective Cohort Study)
by: Yuliya O. Vasenyova, et al.
Published: (2024-09-01) -
Effect of CFTR modulators on glucose homeostasis in children and young adults with cystic fibrosis-related diabetes: a systematic review
by: Paola Giordano, et al.
Published: (2025-08-01) -
Analysis of Ivacaftor drug approval for cystic fibrosis patients with gating mutations.
by: Nemirajaiah, S.
Published: (2021-08-01) -
Avances en el tratamiento de la fibrosis quística: los moduladores de la CFTR
by: Maria Dolores Pastor-Vivero, et al.
Published: (2025-05-01) -
A Retrospective, Longitudinal Registry Study on the Long-Term Durability of Ivacaftor Treatment in People with Cystic Fibrosis
by: Christian Merlo, et al.
Published: (2024-09-01)